Travere Therapeutics
(NASDAQ:TVTX)
$6.30
-0.30[-4.55%]
At close: May 10
$6.30
0[0.00%]
After Hours: 5:59PM EDT
Q1 2024 Earnings were released on Mon May 6th, after the market close
The most recent conference call was at 16:30 PM, 6 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Travere Therapeutics Stock (NASDAQ:TVTX), Quotes and News Summary

Travere Therapeutics Stock (NASDAQ: TVTX) stock price, news, charts, stock research, profile.

Open$6.660
Close$6.300
Volume / Avg.974.836K / 1.266M
Day Range6.260 - 6.880
52 Wk Range5.120 - 19.542
Market Cap$479.613M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
48
Short Interest
17.44%
Days to Cover8.72

Recent News

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at 
Vandana Singh
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday.
Lisa Levin
Crude Oil Moves Lower; AutoZone Profit Tops Views
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500 also fell, dropping, 0.07% to 4,566.73.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Jan
1
1
Feb
1
1
Mar
2
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
TVTX
KALV

FAQ

Q

How do I buy Travere Therapeutics (TVTX) stock?

A

You can purchase shares of Travere Therapeutics (NASDAQ: TVTX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Travere Therapeutics's (TVTX) competitors?

A

Other companies in Travere Therapeutics’s space includes: KalVista Pharma (NASDAQ:KALV), Humacyte (NASDAQ:HUMA), Valneva (NASDAQ:VALN), Celcuity (NASDAQ:CELC) and Korro Bio (NASDAQ:KRRO).

Q

What is the target price for Travere Therapeutics (TVTX) stock?

A

The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by HC Wainwright & Co. on Tuesday, May 7, 2024. The analyst firm set a price target for 19.00 expecting TVTX to rise to within 12 months (a possible 201.59% upside). 33 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Travere Therapeutics (TVTX)?

A

The stock price for Travere Therapeutics (NASDAQ: TVTX) is $6.3 last updated May 10, 2024 at 5:59 PM EDT.

Q

Does Travere Therapeutics (TVTX) pay a dividend?

A

There are no upcoming dividends for Travere Therapeutics.

Q

When is Travere Therapeutics (NASDAQ:TVTX) reporting earnings?

A

Travere Therapeutics’s Q2 earnings are confirmed for Thursday, August 1, 2024.

Q

Is Travere Therapeutics (TVTX) going to split?

A

There is no upcoming split for Travere Therapeutics.

Q

What sector and industry does Travere Therapeutics (TVTX) operate in?

A

Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch